Open-label extension of subcutaneous efgartigimod PH20 in active idiopathic inflammatory myopathy

Phase 3, open-label, single-arm trial of efgartigimod alfa in Autoimmune Myopathies, sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent adverse events, adverse events of special interest, and serious adverse events and Changes and abnormalities in vital signs, ECG, and laboratory parameters. Planned start Sep 2023; status: authorised.